Stem cell therapy for hypoplastic left heart syndrome mechanism, clinical application, and future directions

Circulation Research

Volumn 123, Issue 2, 2018, Pages 288-300

  Bittle, Gregory J ^a   Morales, David ^a   Deatrick, Kristopher B ^a   Parchment, Nathaniel ^a   Saha, Progyaparamita ^a   Mishra, Rachana ^a   Sharma, Sudhish ^a   Pietris, Nicholas ^a   Vasilenko, Alexander ^a   Bor, Casey ^a   Ambastha, Chetan ^a   Gunasekaran, Muthukumar ^a   Li, Deqiang ^a   Kaushal, Sunjay ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cell transplantation; Heart failure; Hypoplastic left heart syndrome; Myocardial infarction; Stem cells

Indexed keywords

STEM CELL FACTOR;

BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC STEM CELL; CARDIOSPHERE DERIVED STEM CELL; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; NONHUMAN; PEDIATRIC PATIENT; PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TIME FACTOR; TREATMENT DURATION; UMBILICAL CORD BLOOD CELL; ADVERSE EVENT; CLASSIFICATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; PATHOPHYSIOLOGY; PROCEDURES; STEM CELL;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPOPLASTIC LEFT HEART SYNDROME; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 85056488795     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.311206     Document Type: Review

References (102)

1. Zhou Y, Wang S, Yu Z, Hoyt JR, Sachdev V, Vincent P, Arai A, Kwak M, Burkett S, Horvath K. Direct injection of autologous stem cells improves myocardial function. Biochem Biophys Res Commun. 2009;390:902-907.
2. Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017;136:2373-2385. doi: 10.1161/ CIRCULATIONAHA.117.029607.
3. Fixler DE, Nembhard WN, Salemi JL, Ethen MK, Canfield MA. Mortality in first 5 years in infants with functional single ventricle born in Texas, 1996 to 2003. Circulation. 2010;121:644-650. doi: 10.1161/CIRCULATIONAHA.109.881904.
4. Gordon BM, Rodriguez S, Lee M, Chang RK. Decreasing number of deaths of infants with hypoplastic left heart syndrome. J Pediatr. 2008;153:354-358. doi: 10.1016/j.jpeds.2008.03.009.
5. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-813. doi: 10.1016/j.jpeds.2008.05.059.
6. Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. J Pediatr. 2014;165:228-233. doi: 10.1016/j.jpeds.2014.04.055.
7. Webster G, Zhang J, Rosenthal D. Comparison of the epidemiology and co-morbidities of heart failure in the pediatric and adult populations: a retrospective, cross-sectional study. BMC Cardiovasc Disord. 2006;6:23. doi: 10.1186/1471-2261-6-23.
8. Atallah J, Dinu IA, Joffe AR, Robertson CM, Sauve RS, Dyck JD, Ross DB, Rebeyka IM; tWestern Canadian Complex Pediatric Therapies Follow-Up Group. Two-year survival and mental and psychomotor outcomes after the Norwood procedure: an analysis of the modified Blalock-Taussig shunt and right ventricle-to-pulmonary artery shunt surgical eras. Circulation. 2008;118:1410-1418. doi: 10.1161/CIRCULATIONAHA.107.741579.
9. Altmann K, Printz BF, Solowiejczky DE, Gersony WM, Quaegebeur J, Apfel HD. Two-dimensional echocardiographic assessment of right ventricular function in hypoplastic left heart syndrome. Am J Cardiol. 2000;86:964-968.
10. Si MS, Ohye RG. Stem cell therapy for the systemic right ventricle. Expert Rev Cardiovasc Ther. 2017;15:813-823. doi: 10.1080/14779072. 2017.1379898.
11. Everitt MD, Boyle GJ, Schechtman KB, Zheng J, Bullock EA, Kaza AK, Dipchand AI, Naftel DC, Kirklin JK, Canter CE; Pediatric Heart Transplant Study Investigators. Early survival after heart transplant in young infants is lowest after failed single-ventricle palliation: a multi-institutional study. J Heart Lung Transplant. 2012;31:509-516. doi: 10.1016/j.healun.2011.12.013.
12. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
13. Becker AJ, Mcculloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452-454.
14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317. doi: 10.1080/14653240600855905.
15. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661-669. doi: 10.1096/fj.05-5211com.
16. Du YY, Zhou SH, Zhou T, Su H, Pan HW, Du WH, Liu B, Liu QM. Immuno-inflammatory regulation effect of mesenchymal stem cell transplantation in a rat model of myocardial infarction. Cytotherapy. 2008;10:469-478. doi: 10.1080/14653240802129893.
17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815-1822. doi: 10.1182/blood-2004-04-1559.
18. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10.1016/j.jacc.2009.06.055.
19. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10.1001/jama.2012.25321.
20. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69:526-537. doi: 10.1016/j.jacc.2016.11.009.
21. E G. Current status of umbilical cord blood hematopoietic stem cell transplantation. Experimental Hematology. 2000;28:1197-1205.
22. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103:1669-1675. doi: 10.1182/blood-2003-05-1670.
23. Berger MJ, Adams SD, Tigges BM, Sprague SL, Wang XJ, Collins DP, McKenna DH. Differentiation of umbilical cord blood-derived multi-lineage progenitor cells into respiratory epithelial cells. Cytotherapy. 2006;8:480-487. doi: 10.1080/14653240600941549.
24. Nishiyama N, Miyoshi S, Hida N, Uyama T, Okamoto K, Ikegami Y, Miyado K, Segawa K, Terai M, Sakamoto M, Ogawa S, Umezawa A. The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem Cells. 2007;25:2017-2024. doi: 10.1634/stemcells.2006-0662.
25. Leor J, Guetta E, Feinberg MS, Galski H, Bar I, Holbova R, Miller L, Zarin P, Castel D, Barbash IM, Nagler A. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006;24:772-780. doi: 10.1634/stemcells.2005-0212.
26. Yerebakan C, Sandica E, Prietz S, et al. Autologous umbilical cord blood mononuclear cell transplantation preserves right ventricular function in a novel model of chronic right ventricular volume overload. Cell Transplant. 2009;18:855-868. doi: 10.3727/096368909X471170.
27. Ma N, Stamm C, Kaminski A, Li W, Kleine HD, Müller-Hilke B, Zhang L, Ladilov Y, Egger D, Steinhoff G. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. Cardiovasc Res. 2005;66:45-54. doi: 10.1016/j.cardiores.2004.12.013.
28. Bartolucci J, Verdugo FJ, González PL, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase ½ randomized controlled trial (RIMECARD trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121:1192-1204. doi: 10.1161/CIRCRESAHA.117.310712.
29. Barile L, Gherghiceanu M, Popescu LM, Moccetti T, Vassalli G. Human cardiospheres as a source of multipotent stem and progenitor cells. Stem Cells Int. 2013;2013:916837. doi: 10.1155/2013/916837.
30. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marbán E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res. 2010;106:971-980. doi: 10.1161/CIRCRESAHA. 109.210682.
31. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, Smith RR, Lardo AC, Lai S, Steenbergen C, Gerstenblith G, Lange R, Marbán E. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation. 2009;120:1075-1083, 7 p following 1083. doi: 10.1161/CIRCULATIONAHA.108.816058.
32. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, Galang G, Zhang Y, Schoenhoff F, Van Eyk J, Marbán L, Marbán E. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012;125:100-112. doi: 10.1161/CIRCULATIONAHA.111.042598.
33. Kanazawa H, Tseliou E, Malliaras K, et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ Heart Fail. 2015;8:322-332. doi: 10.1161/CIRCHEARTFAILURE.114.001484.
34. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary Cardiosphere-Derived Cells for Heart Regeneration After Myocardial Infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904. doi: 10.1016/S0140-6736(12)60195-0.
35. Chakravarty T, Makkar RR, Ascheim DD, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith RR, Lima JA, Pogoda JM, Marbán L, Henry TD. Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial: rationale and design. Cell Transplant. 2017;26:205-214. doi: 10.3727/096368916X692933.
36. Tallini YN, Greene KS, Craven M, Spealman A, Breitbach M, Smith J, Fisher PJ, Steffey M, Hesse M, Doran RM, Woods A, Singh B, Yen A, Fleischmann BK, Kotlikoff MI. c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci USA. 2009;106:1808-1813.
37. Tang XL, Rokosh DG, Guo Y, Bolli R. Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction. Circ J. 2010;74:390-404.
38. Wehman B, Sharma S, Mishra R, Guo Y, Colletti EJ, Kon ZN, Datla SR, Siddiqui OT, Balachandran K, Kaushal S. Pediatric end-stage failing hearts demonstrate increased cardiac stem cells. Ann Thorac Surg. 2015;100:615-622. doi: 10.1016/j.athoracsur.2015.04.088.
39. Mishra R, Vijayan K, Colletti EJ, Harrington DA, Matthiesen TS, Simpson D, Goh SK, Walker BL, Almeida-Porada G, Wang D, Backer CL, Dudley SC Jr, Wold LE, Kaushal S. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011;123:364-373. doi: 10.1161/CIRCULATIONAHA.110.971622.
40. He JQ, Vu DM, Hunt G, Chugh A, Bhatnagar A, Bolli R. Human cardiac stem cells isolated from atrial appendages stably express c-kit. PLoS One. 2011;6:e27719. doi: 10.1371/journal.pone.0027719.
41. Sharma S, Mishra R, Bigham GE, et al. A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells. Circ Res. 2017;120:816-834. doi: 10.1161/CIRCRESAHA.116.309782.
42. Agarwal U, Smith AW, French KM, et al. Age-dependent effect of pediatric cardiac progenitor cells after juvenile heart failure. Stem Cells Transl Med. 2016;5:883-892. doi: 10.5966/sctm.2015-0241.
43. Agarwal U, George A, Bhutani S, Ghosh-Choudhary S, Maxwell JT, Brown ME, Mehta Y, Platt MO, Liang Y, Sahoo S, Davis ME. Experimental, systems, and computational approaches to understanding the microrna-mediated reparative potential of cardiac progenitor cell-derived exosomes from pediatric patients. Circ Res. 2017;120:701-712. doi: 10.1161/CIRCRESAHA.116.309935.
44. Bolli R, Chugh AR, D'Amario D, et al. Cardiac Stem Cells in Patients With Ischaemic Cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857. doi: 10.1016/S0140-6736(11)61590-0.
45. Sultana N, Zhang L, Yan J, Chen J, Cai W, Razzaque S, Jeong D, Sheng W, Bu L, Xu M, Huang GY, Hajjar RJ, Zhou B, Moon A, Cai CL. Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun. 2015;6:8701. doi: 10.1038/ncomms9701.
46. van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, Middleton RC, Marbán E, Molkentin JD. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014;509:337-341. doi: 10.1038/nature13309.
47. Azhari H, Beyar R, Sideman S. On the human left ventricular shape. Comput Biomed Res. 1999;32:264-282. doi: 10.1006/cbmr.1999.1513.
48. Hori M, Yeliin EL, Sonnenblick EH. Left ventricular diastolic suction as a mechanism of ventricular filling. Jpn Circ J. 1982;46:124-129.
49. CR G. The right ventricle and pulmonary circulation: basic concepts. Rev Esp Cardiol. 2010;63:81-95.
50. Dell'Italia LJ. The right ventricle: anatomy, physiology, and clinical importance. Curr Probl Cardiol. 1991;16:653-720.
51. Sanchez-Quintana D, Anderson RH, Ho SY. Ventricular myoarchitecture in tetralogy of Fallot. Heart. 1996;76:280-286.
52. Nakanishi T, Markwald RR, Baldwin HS, Keller BB, Srivastava D, Yamagishi H. Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology. Japan: Springer; 2016.
53. Tam PP, Parameswaran M, Kinder SJ, Weinberger RP. The allocation of epiblast cells to the embryonic heart and other mesodermal lineages: the role of ingression and tissue movement during gastrulation. Development. 1997;124:1631-1642.
54. Paige SL, Plonowska K, Xu A, Wu SM. Molecular regulation of cardiomyocyte differentiation. Circ Res. 2015;116:341-353. doi: 10.1161/CIRCRESAHA.116.302752.
55. Takeuchi JK, Ohgi M, Koshiba-Takeuchi K, Shiratori H, Sakaki I, Ogura K, Saijoh Y, Ogura T. Tbx5 specifies the left/right ventricles and ventricular septum position during cardiogenesis. Development. 2003;130:5953-5964. doi: 10.1242/dev.00797.
56. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE, Seidman JG. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell. 2001;106:709-721.
57. Fan C, Duhagon MA, Oberti C, Chen S, Hiroi Y, Komuro I, Duhagon PI, Canessa R, Wang Q. Novel TBX5 mutations and molecular mechanism for Holt-Oram syndrome. J Med Genet. 2003;40:e29.
58. McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Srivastava D, Olson EN. The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. Development. 2005;132:189-201. doi: 10.1242/dev.01562.
59. Rutenberg JB, Fischer A, Jia H, Gessler M, Zhong TP, Mercola M. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development. 2006;133:4381-4390. doi: 10.1242/dev.02607.
60. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev cell. 2012;22: 244-254.
61. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-274. doi: 10.1038/nature03940.
62. Bosse K, Hans CP, Zhao N, Koenig SN, Huang N, Guggilam A, LaHaye S, Tao G, Lucchesi PA, Lincoln J, Lilly B, Garg V. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J Mol Cell Cardiol. 2013;60:27-35. doi: 10.1016/j.yjmcc.2013.04.001.
63. Boni A, Urbanek K, Nascimbene A,et al. Notch1 regulates the fate of cardiac progenitor cells. Proc Natl Acad Sci USA. 2008;105:15529-15534.
64. Hinton RB, Martin LJ, Rame-Gowda S, Tabangin ME, Cripe LH, Benson DW. Hypoplastic left heart syndrome links to chromosomes 10q and 6q and is genetically related to bicuspid aortic valve. J Am Coll Cardiol. 2009;53:1065-1071. doi: 10.1016/j.jacc.2008.12.023.
65. Iascone M, Ciccone R, Galletti L, Marchetti D, Seddio F, Lincesso AR, Pezzoli L, Vetro A, Barachetti D, Boni L, Federici D, Soto AM, Comas JV, Ferrazzi P, Zuffardi O. Identification of de novo mutations and rare variants in hypoplastic left heart syndrome. Clin Genet. 2012;81:542-554. doi: 10.1111/j.1399-0004.2011.01674.x.
66. Kobayashi J, Yoshida M, Tarui S, Hirata M, Nagai Y, Kasahara S, Naruse K, Ito H, Sano S, Oh H. Directed differentiation of patient-specific induced pluripotent stem cells identifies the transcriptional repression and epigenetic modification of NKX2-5, HAND1, and NOTCH1 in hypoplastic left heart syndrome. PLoS One. 2014;9:e102796. doi: 10.1371/journal.pone.0102796.
67. Cohen ED, Miller MF, Wang Z, Moon RT, Morrisey EE. Wnt5a and Wnt11 are essential for second heart field progenitor development. Development. 2012;139:1931-1940. doi: 10.1242/dev.069377.
68. Nagy II, Railo A, Rapila R, Hast T, Sormunen R, Tavi P, Räsänen J, Vainio SJ. Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin expression. Cardiovasc Res. 2010;85:100-109. doi: 10.1093/cvr/cvp254.
69. Touma M, Kank X GF, Cass AA, Biniwale R, Xiao X, Eghbali M, Coppola G, Reemtsen B, Wang Y. Wnt11 regulates cardiac chamber development and disease during perinatal maturation. JCI Insight. 2017;2:e94904.
70. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115:176-188. doi: 10.1161/CIRCRESAHA.113.301129.
71. Schreckenberg R, Rebelo M, Deten A, Weber M, Rohrbach S, Pipicz M, Csonka C, Ferdinandy P, Schulz R, Schlüter KD. Specific mechanisms underlying right heart failure: the missing upregulation of superoxide dis-mutase-2 and its decisive role in antioxidative defense. Antioxid Redox Signal. 2015;23:1220-1232. doi: 10.1089/ars.2014.6139.
72. Salih C, Sheppard MN, Ho SY. Morphometry of coronary capillaries in hypoplastic left heart syndrome. Ann Thorac Surg. 2004;77:903-907; discussion 907. doi: 10.1016/j.athoracsur.2003.07.046.
73. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J and Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl). 2013;91:1315-1327.
74. Ruiter G, Ying Wong Y, de Man FS, Louis Handoko M, Jaspers RT, Postmus PE, Westerhof N, Niessen HW, van der Laarse WJ, Vonk-Noordegraaf A. Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. J Heart Lung Transplant. 2013;32:231-240. doi: 10.1016/j.healun.2012.09.025.
75. Zungu-Edmondson M, Shults NV, Wong CM, Suzuki YJ. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Cardiovasc Res. 2016;110:30-39. doi: 10.1093/cvr/cvw014.
76. Piao L, Marsboom G, Archer SL. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl). 2010;88:1011-1020. doi: 10.1007/s00109-010-0679-1.
77. Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui OT, Bigham G, Li T, Aiello E, Murthi S, Pittenger M, Griffith B, Kaushal S. Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. Am J Physiol Heart Circ Physiol. 2016;310:H1816-H1826. doi: 10.1152/ajpheart.00955.2015.
78. Wehman B, Pietris N, Bigham G, Siddiqui O, Mishra R, Li T, Aiello E, Jack G, Wang W, Murthi S, Sharma S, Kaushal S. Cardiac progenitor cells enhance neonatal right ventricular function after pulmonary artery banding. Ann Thorac Surg. 2017;104:2045-2053. doi: 10.1016/j.athoracsur.2017.04.058.
79. Davies B, Elwood NJ, Li S, Cullinane F, Edwards GA, Newgreen DF, Brizard CP. Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg. 2010;89:585-593, 593.e1. doi: 10.1016/j.athoracsur.2009.10.035.
80. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011;50:280-289. doi: 10.1016/j.yjmcc.2010.08.005.
81. Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116:653-664. doi: 10.1161/CIRCRESAHA.116.304671.
82. Ishigami S, Ohtsuki S, Eitoku T, et al. Intracoronary cardiac progenitor cellsinsingleventriclephysiology:thePERSEUS(CardiacProgenitorCell Infusion to Treat Univentricular Heart Disease) randomized phase 2 trial. CircRes.2017;120:1162-1173.doi:10.1161/CIRCRESAHA.116.310253.
83. Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015;150:1198-1207, 1208.e1. doi: 10.1016/j.jtcvs.2015.06.076.
84. Kaushal S, Wehman B, Pietris N, et al. Study design and rationale for ELPIS: a phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. Am Heart J. 2017;192:48-56. doi: 10.1016/j.ahj.2017.06.009.
85. van den Akker F, Deddens JC, Doevendans PA, Sluijter JP. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2013;1830:2449-2458. doi: 10.1016/j.bbagen.2012.08.026.
86. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011;8:389-398. doi: 10.1016/j.stem.2011.02.002.
87. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation. 2012;126:S46-S53. doi: 10.1161/CIRCULATIONAHA. 111.084699.
88. Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail. 2013;19:342-353. doi: 10.1016/j.cardfail.2013.03.011.
89. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, Beltrami CA, Bussani R, Beltrami AP, Quaini F, Bolli R, Leri A, Kajstura J, Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci USA. 2005;102:8692-8697. doi: 10.1073/pnas.0500169102.
90. Traverse JH, Henry TD, Pepine CJ, et al; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308:2380-2389. doi: 10.1001/jama.2012.28726.
91. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy ResearchNetwork. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110-2119. doi: 10.1001/jama.2011.1670.
92. Ohye R, JV S, Eghtesady P, et al. Cause, timing, and location of death in the single ventricle reconstruction trial. J Thorac Cardiovasc Surg. 2012;144:907-914.
93. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 2016;1:831-841. doi: 10.1001/jamacardio.2016.2225.
94. Parmacek MS, Epstein JA. Cardiomyocyte renewal. N Engl J Med. 2009;361:86-88. doi: 10.1056/NEJMcibr0903347.
95. Mollova M, Bersell K, Walsh S, Savla J, Das LT, Park SY, Silberstein LE, Dos Remedios CG, Graham D, Colan S, Kuhn B. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci USA. 2013;110:1446-1451.
96. Rupp S, Jux C, Bönig H, Bauer J, Tonn T, Seifried E, Dimmeler S, Zeiher AM, Schranz D. Intracoronary bone marrow cell application for terminal heart failure in children. Cardiol Young. 2012;22:558-563. doi: 10.1017/S1047951112000066.
97. Burkhart HM, Qureshi MY, Peral SC, O'Leary PW, Olson TM, Cetta F, Nelson TJ; Wanek Program Clinical Pipeline Group. Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. JThorac Cardiovasc Surg. 2015;149:e35-e37. doi: 10.1016/j.jtcvs.2014.10.093.
98. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, Pittenger MF, van Zijl PC, Huang J, Bulte JW. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39:1569-1574. doi: 10.1161/STROKEAHA.107.502047.
99. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, Wang W, Yerebakan C, Li W, Gaebel R, Li RK, Vollmar B, Steinhoff G, Ma N. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77:370-376. doi: 10.1016/j.mvr.2009.02.001.
100. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006;27:1114-1122. doi: 10.1093/eurheartj/ehi818.
101. Prathipati P NS, Mishra PK. Stem cell-derived exosomes, autophagy, extracellular matrix turnover, and miRNAs in cardiac regeneration during stem cell therapy. Stem Cell Rev Rep. 2016;13:79-91.
102. Wehman B, Siddiqui OT, Mishra R, Sharma S, Kaushal S. Stem cell therapy for congenital heart disease: toward translation. Cardiol Young. 2015;25:58-66.